Have a feature idea you'd love to see implemented?
Let us know!
VRNA Verona Pharma plc
Price (delayed)
$37.86
Market cap
$3.1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2
Enterprise value
$2.99B
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved,
Highlights
Verona Pharma's quick ratio has shrunk by 57% YoY but it has increased by 47% QoQ
VRNA's equity has dropped by 50% year-on-year and by 22% since the previous quarter
The EPS has declined by 25% since the previous quarter
Key stats
What are the main financial stats of VRNA
Market
Valuations
Earnings
Shares outstanding
81.83M
Market cap
$3.1B
Enterprise value
$2.99B
Price to earnings (P/E)
N/A
Price to book (P/B)
23.57
Price to sales (P/S)
548.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
531.01
Revenue
$5.62M
EBIT
-$137.91M
EBITDA
-$136.9M
Free cash flow
-$103.81M
Per share
Balance sheet
Liquidity
EPS
-$2
Free cash flow per share
-$1.27
Book value per share
$1.61
Revenue per share
$0.07
TBVPS
$4.68
Total assets
$381.82M
Total liabilities
$251.33M
Debt
$224.33M
Equity
$130.49M
Working capital
$336.3M
Debt to equity
1.72
Current ratio
13.03
Quick ratio
12.27
Net debt/EBITDA
0.82
Margins
Efficiency
Dividend
EBITDA margin
-2,434.3%
Gross margin
90.3%
Net margin
-2,733.3%
Operating margin
-2,762.8%
Return on assets
-43.5%
Return on equity
-79.5%
Return on invested capital
-93.5%
Return on capital employed
-39%
Return on sales
-2,452.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRNA stock price
How has the Verona Pharma stock price performed over time
Intraday
-2.55%
1 week
7.04%
1 month
8.26%
1 year
163.83%
YTD
90.44%
QTD
31.6%
Financial performance
How have Verona Pharma's revenue and profit performed over time
Revenue
$5.62M
Gross profit
$5.08M
Operating income
-$155.38M
Net income
-$153.72M
Gross margin
90.3%
Net margin
-2,733.3%
The operating income has plunged by 145% YoY and by 19% from the previous quarter
The operating margin has soared by 80% YoY
The net margin has soared by 75% year-on-year
VRNA's net income is down by 23% QoQ
Growth
What is Verona Pharma's growth rate over time
Valuation
What is Verona Pharma stock price valuation
P/E
N/A
P/B
23.57
P/S
548.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
531.01
The EPS has declined by 25% since the previous quarter
VRNA's P/B is 153% above its last 4 quarters average of 9.3
VRNA's equity has dropped by 50% year-on-year and by 22% since the previous quarter
Efficiency
How efficient is Verona Pharma business performance
Verona Pharma's ROA has plunged by 153% YoY and by 15% from the previous quarter
The return on sales has surged by 77% year-on-year
Verona Pharma's ROE has decreased by 44% from the previous quarter
The ROIC has grown by 34% YoY and by 23% from the previous quarter
Dividends
What is VRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRNA.
Financial health
How did Verona Pharma financials performed over time
Verona Pharma's total assets is 52% more than its total liabilities
Verona Pharma's current ratio has plunged by 58% YoY but it has soared by 51% from the previous quarter
Verona Pharma's quick ratio has shrunk by 57% YoY but it has increased by 47% QoQ
The debt is 72% greater than the equity
VRNA's equity has dropped by 50% year-on-year and by 22% since the previous quarter
Verona Pharma's debt to equity has increased by 32% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.